Xeljanz & Onglyza – Emerging Litigations

XELJANZ (Tofacitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs).

Xeljanz is a medicine that affects immune system. Patients treated with Xeljanz are at increased risk for developing serious infections leading to hospitalization or death, including active tuberculosis (TB), invasive fungal infections, bacterial, viral and other infections due to opportunistic pathogens.
Case Evaluation Criteria:
  1. Whether the patient was prescribed Xeljanz?
  2. Reason for Xeljanz Prescription?
  3. Did the patient have any pre-existing conditions, allergies or contraindications for Xeljanz?
    Read More

ONGLYZA belongs to a class of drugs known as Incretin Mimetics, which stimulate the production of insulin in the pancreas to help regulate blood sugar levels in patients with Type-2 diabetes. It was approved for the treatment of Type-2 diabetes in 2009.

Heart failure is not the only potentially fatal condition with a documented link to Onglyza. In 2013, the FDA warned that people taking Onglyza and similar drugs may be more likely to develop pancreatic cancer.
 –
Case Evaluation Criteria:
  1. Whether the patient was prescribed Onglyza?
  2. Reason for Onglyza Prescription?
  3. Did the patient have any pre-existing conditions, allergies or contraindications for Onglyza?
    Read More